Skip to main content
Midas Edge

60 DEGREES PHARMACEUTICALS, INC.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

SXTP$0.52-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Condensed Statements of Shareholders’ Equity

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY(UNAUDITED)

For the Three and Nine Months Ended September 30, 2025
Series A Preferred Stock · Common Stock(1) · Additional Paid-In Capital(1) · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Shareholders’ Equity Attributable to 60P · Noncontrolling Interest on Shareholders · Total Shareholders' Equity
Shares · Amount · Shares · Amount
Balance—December 31, 202476,480$9,567,439566,908$57$34,860,590$(40,527,957)$135,471$4,035,600$(80,594)$3,955,006
Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)--204,31220804,326--804,346-804,346
Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)--300,70030908,597--908,627-908,627
Issuance of common stock upon exercise of Pre-Funded Warrants--385,200381,888--1,926-1,926
Issuance of shares for annual performance bonuses, net of shares withheld for taxes--15,8092103,542--103,544-103,544
Share-based compensation expense----142,645--142,645-142,645
Net foreign translation loss-----(9,904)(9,904)-(9,904)
Net loss-----(1,876,549)-(1,876,549)(752)(1,877,301)
Share rounding adjustment for reverse stock split--(38)------
Balance— March 31, 2025 (unaudited)76,480$9,567,4391,472,891$147$36,821,588$(42,404,506)$125,567$4,110,235$(81,346)$4,028,889
Share-based compensation expense----34,503--34,503-34,503
Net foreign translation gain------17,24217,242-17,242
Net loss-----(1,733,726)-(1,733,726)(1,204)(1,734,930)
Balance— June 30, 2025 (unaudited)76,480$9,567,4391,472,891$147$36,856,091$(44,138,232)$142,809$2,428,254$(82,550)$2,345,704
Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)--1,753,3141754,281,125--4,281,300-4,281,300
Issuance of common stock upon exercise of Pre-Funded Warrants--878,26488790--878-878
Share-based compensation expense----34,882--34,882-34,882
Net foreign translation gain------1,2301,230-1,230
Net loss-----(2,316,324)-(2,316,324)(712)(2,317,036)
Balance— September 30, 2025 (unaudited)76,480$9,567,4394,104,469$410$41,172,888$(46,454,556)$144,039$4,430,220$(83,262)$4,346,958

(1) Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

For the Three and Nine Months Ended September 30, 2024
Series A Preferred Stock · Common Stock(1) · Additional Paid-In Capital(1) · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Shareholders’ Equity Attributable to 60P · Noncontrolling Interest on Shareholders · Total Shareholders' Equity
Shares · Amount · Shares · Amount
Balance—December 31, 202378,803$9,858,04096,847$10$27,457,373$(32,580,850)$135,561$4,870,134$(72,038)$4,798,096
Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6)--87,68391,898,287--1,898,296-1,898,296
Issuance of common stock upon exercise of Pre-Funded Warrants--8,32614,994--4,995-4,995
Issuance of shares for RSUs--3,201-------
Net foreign translation loss------(3,894)(3,894)-(3,894)
Net income (loss)-----430,470-430,470(2,485)427,985
Balance— March 31, 2024 (unaudited)78,803$9,858,040196,057$20$29,360,654$(32,150,380)$131,667$7,200,001$(74,523)$7,125,478
Issuance of common stock upon exercise of Pre-Funded Warrants--8,32614,994--4,995-4,995
Issuance of shares for RSUs--1,069-------
Voluntary return of shares issued to vendor for services--(2,000)-------
Net foreign translation gain------3,1373,137-3,137
Net loss-----(4,172,755)-(4,172,755)(1,471)(4,174,226)
Balance— June 30, 2024 (unaudited)78,803$9,858,040203,452$21$29,365,648$(36,323,135)$134,804$3,035,378$(75,994)$2,959,384
Voluntary conversion of Series A Preferred Stock into common stock(2,323)(290,601)14,6671290,600-----
Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6)--135,568141,729,796--1,729,810-1,729,810
Issuance of warrants in Private Placement, net of offering costs paid at closing and deferred offering costs (Note 6)----3,414,502--3,414,502-3,414,502
Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment--18,7102(2)-----
Share-based compensation expense----15,246--15,246-15,246
Net foreign translation gain------4,4034,403-4,403
Net loss-----(2,159,785)-(2,159,785)(713)(2,160,498)
Balance— September 30, 2024 (unaudited)76,480$9,567,439372,397$38$34,815,790$(38,482,920)$139,207$6,039,554$(76,707)$5,962,847

(1) Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.